For research and educational purposes only. Not medical advice.

Methylene blue Reference

Educational, not medical advice reference for Methylene blue: Nootropic, Metabolic; regulatory status, evidence posture, source review, and schedule notes. A…

Reference summary

Methylene blue is label-verified for methemoglobinemia. Low-dose nootropic literature is preclinical and small human pilot trials.

Categories
Nootropic, Metabolic
Aliases
Provayblue, Methylthioninium chloride, Methylene blue USP
Evidence posture
human — FDA-approved at therapeutic doses for methemoglobinemia. Low-dose nootropic / cognitive use is off-label. Concomitant SSRIs / MAOIs / serotonergic agents can produce serotonin syndrome — methylene blue is a potent MAO-A inhibitor at therapeutic doses.
Regulatory status
FDA-approved prescription medication (Provayblue) for acquired methemoglobinemia. Low-dose nootropic / cognitive use is off-label. Not a controlled substance.
Content review status
label verified

Selected public sources